Over the last years, we have witnessed an increasing number of clinical practice guidelines in HCC produced by different bodies, not only with regard to diagnosis and treatment but also in several ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

End-of-life (EOL) outcomes and healthcare utilization for patients with hepatocellular carcinoma (HCC) who received immune checkpoint inhibition (ICI). This is an ASCO Meeting Abstract from the 2025 ...

China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...

Immune Checkpoint Inhibitors (ICIs): Recent guidelines ... Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions. Journal of Clinical and ...

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Many countries either lack appropriate clinical practice guidelines for the diagnosis and treatment of HCC or the quality of their guidelines has never been evaluated. The main objective of our ...